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The health of neurons is critically dependent on the
relative signaling intensities of survival-promoting
synaptic anddeath-inducing extrasynapticNMDA re-
ceptors. Here, we show that BDNF is a regulator of
this balance and promotes neuroprotection by
reducing toxic NMDA receptor signaling. BDNF acts
by initiating synaptic NMDA-receptor/nuclear-cal-
cium-driven adaptogenomics, leading to increased
expression of inhibin b-A (inhba). Inhibin b-A (its
homodimer is known as activin A) in turn reduces
neurotoxic extrasynaptic NMDA-receptor-mediated
calcium influx, thereby shielding neurons against
mitochondrial dysfunction, a major cause of excito-
toxicity. Thus, BDNF induces acquired neuroprotec-
tion by enhancing synaptic activity and lowering ex-
trasynaptic NMDA receptor death signaling through
a nuclear calcium-inhibin b-A pathway. This process,
which confers protection against ischemic brain
damage in a mouse stroke model, may be compro-
mised in Huntington’s disease, Alzheimer’s disease,
or aging-related neurodegenerative conditions that
are associated with reduced BDNF levels and/or
enhanced extrasynaptic NMDA receptor signaling.INTRODUCTION
BDNF is a versatile and multifunctional growth factor implicated
in the control of a wide spectrum of adaptive processes in the
developing and adult brain, ranging from modulation of synaptic
connectivity and excitability to neuroprotection (Park and Poo,
2013). BDNF acts through the high-affinity tyrosine receptor ki-
nase B (TrkB) receptor, which upon ligand binding activates
downstream effector kinases and signaling pathways including
phosphatidylinositol 3-kinase (PI3K)/Akt and the Ras/extracel-
lular-signal-regulated kinase 1/2 (ERK1/2) cascade. The induc-
tion of these signaling pathways is generally thought to mediate
the neuroprotective effects of BDNF against toxic insults such as
bath-applied glutamate, hypoxic ischemia, serumdeprivation, orCellcamptothecin-induced apoptosis (Almeida et al., 2005; Atwal
et al., 2000; Han and Holtzman, 2000; Hetman et al., 1999).
The PI3K/Akt and Ras/ERK1/2 pathways are indeed potent neu-
roprotectors and are also involved in pro-survival processes
activated by neuronal activity (Papadia et al., 2005; Perkinton
et al., 2002). However, the buildup of a long-lasting neuroprotec-
tive shield upon induction of synaptic activity, known as ‘‘ac-
quired neuroprotection’’ (Bading, 2013; Zhang et al., 2009),
results primarily from the activation of synaptic NMDA receptors
and the subsequent generation of nuclear calcium transients that
serve as the on switch of a neuroprotective gene program (Har-
dingham et al., 2001, 2002; Papadia et al., 2005; Zhang et al.,
2007, 2009). The induction of this survival-enhancing set of
genes is part of a broad, nuclear-calcium-regulated change in
the transcriptional profile of synaptically activated neurons,
here termed ‘‘adaptogenomics,’’ which is required for the long-
term implementation of virtually all structural and functional
adaptations in the brain (Bading, 2013).
Both synaptic dysfunction and impaired NMDA receptor
signaling as well as decreased BDNF levels are implicated in
the etiology of several neurodegenerative diseases (Zuccato
and Cattaneo, 2009). We therefore reasoned that BDNF-induced
survival and acquired neuroprotection are mechanistically linked
and share the requirement for synaptic NMDA receptors and nu-
clear-calcium-regulated transcriptional events. This hypothesis
is supported by previous observations that BDNF can increase
synaptic AMPA- and NMDA-receptor-mediated currents, as
well as whole-cell NMDA currents and calcium responses (Car-
mignoto et al., 1997; Poo, 2001). Our study revealed that, under
our conditions, the buildup of a neuroprotective shield following
BDNF treatment of hippocampal neurons is not mediated by
PI3K/Akt and Ras/ERK1/2 signaling but instead is the result of
the ability of BDNF to promote synaptic activity and to induce
the expression of inhibin b-A (inhba)—an activity-driven neuro-
protective gene regulated by synaptic NMDA receptors and nu-
clear calcium (Zhang et al., 2009). Themechanism throughwhich
the BDNF-inhibin b-A-signaling pathway boosts resistance
against excitotoxicity involves a dephosphorylation of NMDA re-
ceptor subunit NR2B at tyrosine residue 1472, a decrease in
neurotoxic extrasynaptic NMDA-receptor-mediated calcium
influx, and reduced calcium-overload-induced mitochondrial
dysfunction. These results indicate that BDNF induces neuro-
protection primarily through the control of the balance betweenReports 12, 1353–1366, August 25, 2015 ª2015 The Authors 1353
Figure 1. Role of Synaptic Activity, Synaptic NMDA Receptors, PI3K, and ERK1/2 Signaling in BDNF-Induced Neuroprotection
(A) Analysis of NMDA-induced excitotoxicity (10 min exposure to 20 mMNMDA) in untreated hippocampal neurons and neurons pre-treated for 8 hr as indicated
with BDNF (100 ng/ml), TTX (1 mM), and APV (250 mM). TTX and APVwere applied 30min prior to BDNF, and all drugs were washed out before NMDA application.
Cell death was analyzed 18–20 hr after the excitotoxic insult.
(B–D) Immunoblot analysis using phosphorylation site-specific antibodies to TrkB, Akt, and ERK1/2 and antibodies to TrkB, Akt, and ERK1/2 of lysates obtained
from hippocampal neurons stimulated with BDNF (100 ng/ml) for 30 min, hippocampal neurons treated with TTX (1 mM) or MK-801 (10 mM) for 30 min prior to and
during 30min of BDNF exposure (B; quantification of three independent repeats is shown in C), and from hippocampal neurons stimulated with BDNF (100 ng/ml)
for 4 hr and neurons treated with PD98059 (20 mM) or LY294002 (20 mM) for 30min prior to and during 4 hr of BDNF exposure (D). Representative immunoblots are
shown.
(E–H) Analysis of NMDA-induced excitotoxicity in untreated hippocampal neurons and neurons pre-treated with the indicated combination of BDNF (100 ng/ml),
LY294002 (20 mM; E), PD98059 (20 mM in F and 20 mMor 50 mM in H), and LY294002 plus PD98059 (PD + LY, each at 20 mM; G) for 8 hr (n = 4 for all experiments).
Statistical analysis for each experiment was determined by ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1. All data are expressed as mean ± SEM.synaptic versus extrasynaptic NMDA receptor signaling via the
nuclear calcium-inhibin b-A pathway.
RESULTS
BDNF-Induced Neuroprotection Requires Synaptic
Activity and the Activation of Synaptic NMDA Receptors
To investigate a possible role of synaptic activity and synaptic
NMDA receptor activation in BDNF-induced neuroprotection,
we first confirmed that BDNF protects cultured mouse hippo-
campal neurons from NMDA-induced excitotoxic cell death.
We found that 8-hr pre-treatment with BDNF indeed robustly
reduced NMDA-induced neurotoxicity (Figure 1A). Both the
voltage-dependent sodium channel blocker, TTX, and the1354 Cell Reports 12, 1353–1366, August 25, 2015 ª2015 The Authoreversible NMDA receptor antagonist, APV, completely elimi-
nated the neuroprotective effect of BDNF (Figure 1A), suggesting
that both neuronal activity (action potentials) and NMDA recep-
tor activity are critical for BDNF-induced neuroprotection.
Next, we investigated whether the blockade of BDNF-induced
neuroprotection by TTX or an NMDA receptor antagonist results
from a failure of BDNF to activate TrkB phosphorylation and/or
its downstream PI3K/Akt and/or Ras/ERK1/2-signaling path-
ways. Immunoblot analysis using antibodies specific for the
phosphorylated (i.e., activated) forms of TrkB, Akt, and ERK1/2
revealed that BDNF treatment induced a robust phosphoryla-
tion and activation of TrkB, Akt, and ERK1/2 in hippocampal
neurons, which was sensitive to neither TTX nor the NMDA re-
ceptor blocker, MK-801 (Figures 1B and 1C). Thus, under ourrs
experimental conditions, action potentials and NMDA receptors
are not required for the activation of PI3K/Akt and/or Ras/
ERK1/2 by exogenous BDNF and, unexpectedly, activation of
these intracellular signaling pathways does not mediate the
BDNF-induced neuroprotection against NMDA toxicity.
To further test this hypothesis, we next investigated whether
inhibition of ERK1/2 with PD98059 or PI3K with LY294002,
individually or in combination, affect BDNF-induced neuropro-
tection against excitotoxicity. Immunoblot analysis showed
that PD98059 and LY294002 selectively inhibited BDNF-induced
activation of ERK1/2 and PI3K/Akt, respectively (Figure 1D).
However, pre-treatment with PD98059, LY294002, or with a
combination of both did not compromise BDNF-induced neuro-
protection against NMDA-induced excitotoxicity (Figures 1E–
1G). These results suggest that, in our experimental conditions,
neither PI3K/Akt nor ERK1/2 is required for BDNF-induced neu-
roprotection. Consistent with the observations that inhibition
of the ERK1/2 pathway can protect neurons against damage
caused by glutamate-induced excitotoxicity, focal cerebral
ischemia, and traumatic brain injury (Irving and Bamford,
2002), we found that treatment with PD98059 reduced NMDA-
induced cell death (Figure 1H) to an extent similar to that
observed in neurons treated with either BDNF or both BDNF
and PD98059 (Figure 1F). Because of this neuroprotective activ-
ity of PD98059, it is not possible to assess the contribution of
ERK1/2 signaling to BDNF-induced neuroprotection apart from
concluding that their protective efficacies are not additive.
To investigate whether BDNF-induced neuroprotection gener-
alizes to other toxic insults, we tested H2O2-induced toxicity as a
model for oxidative stress. In this model, BDNF afforded consid-
erable neuroprotection, which was not blocked by either
PD98059 or LY294002. In addition, PD98059 alone provided
some protection against H2O2-induced toxicity as it did against
NMDA-induced toxicity (Figure S1A). Because BDNF is a ubiqui-
tous neurotrophic factor, we finally tested whether the signaling
mechanism observed in hippocampal neurons is also functional
in cortical neurons. BDNF protection against NMDA-induced
toxicity in cultured cortical neurons mimicked these results in
the hippocampus in several respects, with the exception that
PD98059 was not by itself protective (Figure S1A). This suggests
that the involvement of ERK1/2 signaling in BDNF-induced neu-
roprotection may depend on the cell type and the nature of the
toxic stimulus.
BDNF Induces Nuclear Calcium Signaling that Mediates
Neuroprotection
Given the importance of calcium influx through synaptic NMDA
receptors and the subsequent generation of nuclear calcium
transients in acquired neuroprotection (Hardingham et al.,
2001, 2002; Papadia et al., 2005; Zhang et al., 2007, 2009) and
that BDNF can activate glutamatergic synaptic release (Car-
mignoto et al., 1997; Poo, 2001) and cytosolic calcium signals
in cultured hippocampal and cortical neurons (Berninger et al.,
1993; Mizoguchi and Nabekura, 2003), we investigated the
possibility that BDNF treatment initiates nuclear calcium
signaling in our cultured hippocampal neurons. We found that
miniature excitatory postsynaptic currents (mEPSCs), recorded
in the presence of TTX, underwent an increase in both frequencyCell(1/inter-event interval) and amplitude in response to acute bath
application of BDNF (Figures S2A and S2B). Fluo-3 calcium
imaging experiments revealed that exposure of hippocampal
neurons to BDNF led to periodic increases in the intracellular
calcium concentration, which were eliminated by either TTX or
the NMDA receptor antagonist MK-801 (Figure 2A; data not
shown). Thus, BDNF-induced calcium transients require action
potentials and NMDA receptor activation, which are likely due
to BDNF causing membrane depolarization, action potential
generation, and enhancing glutamatergic synaptic transmission
through both pre- and postsynaptic TrkB receptors (Poo, 2001).
To investigate whether BDNF-induced calcium transients invade
the cell nucleus (which would be necessary to activate the
genomic neuroprotective program; Hardingham et al., 2002;
Papadia et al., 2005; Zhang et al., 2007, 2009), we used a recom-
binant adeno-associated virus (rAAV) to express the nuclear
calcium sensor, GCaMP2.0-NLS-myc. GCaMP2.0-NLS-myc
consists of GCaMP2.0 fused to a myc tag and a nuclear localiza-
tion signal (NLS), which targets this recombinant calcium indica-
tor to the cell nucleus (Bengtson et al., 2010). In hippocampal
neurons infected with rAAV-GCaMP2-NLS-myc, we could
detect robust nuclear calcium signals after BDNF treatment
that were blocked by MK-801 and TTX (Figure 2B). Nuclear
calcium transients evoked by the activation of synaptic NMDA
receptors following treatment of the cultures with the GABAA re-
ceptor antagonist, bicuculline (Hardingham et al., 2001, 2002),
are shown for comparison (Figure 2C).
To investigate a possible causal link between BDNF-induced
nuclear calcium transients, the activation of nuclear-calcium-
controlled genomic events, and the neuroprotection afforded
by BDNF treatment, we expressed CaMBP4, an inhibitor of nu-
clear calcium signaling in hippocampal neurons. CaMBP4 is a
nuclear protein that consists of four tandem repeats of the
calmodulin-binding peptide M13 derived frommyosin light chain
kinase, which binds the nuclear calcium/calmodulin complex,
thereby specifically inactivating nuclear calcium/calmodulin-
regulated events (Mauceri et al., 2011; Papadia et al., 2005;
Zhang et al., 2007, 2009). Immunoblot analysis revealed that,
compared to control (i.e., uninfected neurons and neurons in-
fected with rAAV-mCherry), hippocampal neurons infected with
rAAV-CaMBP4-mCherry (to express a mCherry-tagged version
of CaMBP4) showed equivalent BDNF-induced phosphorylation
and activation of TrkB, Akt, and ERK1/2 (Figures 2D and 2E). In
contrast, CaMBP4-mCherry expression completely blocked
the neuroprotective effects of 10 and 100 ng/ml BDNF treat-
ments (Figure 2F). These results indicate that the BDNF-induced
nuclear calcium transients mediate the neuroprotective effects
of BDNF against NMDA-induced excitotoxicity independent of
TrkB, Akt, and ERK1/2 activation.
Inhba—A Nuclear-Calcium- and CBP-Regulated,
BDNF-Induced Gene
A search for neuroprotective genes whose expression in hippo-
campal neurons changes upon BDNF stimulation in a TTX-sen-
sitive manner drew our attention to inhba (Figures 3A, S3A,
and S3B). The inhba gene encodes the inhibin b-A subunit, which
dimerizes to form the biologically active protein, activin A, a
member of the transforming growth factor b (TGF-b) family.Reports 12, 1353–1366, August 25, 2015 ª2015 The Authors 1355
Figure 2. BDNF Stimulates NMDA-Receptor- and Action-Potential-Dependent Nuclear Calcium Signaling and Induces Nuclear-Calcium-
Dependent Neuroprotection
(A–C) Somatic calcium imaging of uninfected hippocampal neurons loaded with Fluo-3 (A) and nuclear calcium signals measured using GCaMP2.0-NLS
(B and C). After baseline recording, BDNF (100 ng/ml), bicuculline (50 mM), MK-801 (10 mM), and TTX (1 mM) were applied as indicated. Calcium transients evoked
by action potential bursting induced with bicuculline (C) are shown for comparison with the BDNF-induced calcium transients (A and B). Each graph shows a
representative recording from one coverslip, showing traces from individual cells in gray and their average in black (n R 3 independent repeats for all
experiments).
(D and E) Immunoblot analysis using phosphorylation site-specific antibodies to TrkB, Akt, and ERK1/2 and antibodies to TrkB, Akt, and ERK1/2 of lysates
obtained from uninfected hippocampal neurons and neurons infected with rAAV-mCherry and rAAV-CaMBP4-mCherry neurons with or without stimulation for
30 min with BDNF (100 ng/ml). A representative blot is shown (D); quantification of three independent repeats is shown in (E).
(F) Analysis of NMDA-induced cell death in uninfected hippocampal neurons and neurons infected with the indicated rAAVs with or without pre-treatment with
BDNF (100 ng/ml, left panel; 10 ng/ml, right panel) for 8 hr prior to the NMDA insults (n = 3 for each panel). Statistical analysis for each experiment was determined
by ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S2. All data are expressed as mean ± SEM.Activin A and the type I and II activin A receptors (ActRs) are
highly expressed in the developing and adult brain (http://
www.brain-map.org); they can regulate dendritic spine mor-
phology, modulate glutamate neurotransmission, control the
maintenance of long-term memory, and promote neuronal sur-
vival both in vitro and in vivo (Ageta et al., 2010; Mukerji et al.,
2009; Mu¨ller et al., 2006; Tretter et al., 2000). The expression
of inhba is synaptic activity regulated in an NMDA-receptor-
and nuclear-calcium-dependent manner (Zhang et al., 2009).
To investigate a causal link between BDNF-induced nuclear cal-
cium signaling, inhba expression, and neuroprotection, we first
analyzed whether BDNF-induced inhba expression depends
on NMDA receptor activation. Using qRT-PCR, we found that
indeed the induction of inhba expression following stimulation
with BDNF is reduced by TTX or MK-801 (Figure 3A). The
BDNF-dependent induction of inhba expression is followed by1356 Cell Reports 12, 1353–1366, August 25, 2015 ª2015 The Authothe secretion of activin A. Using ELISA analysis of the cultureme-
dium, we detected an increase in activin A secretion 8–18 hr
following BDNF treatment (Figure 3B). We next investigated
the role of nuclear calcium in BDNF-induced inhba expression.
Compared to uninfected neurons and neurons infected with
rAAV-mCherry, both the basal and the BDNF-induced expres-
sion of inhba mRNA were significantly reduced in neurons in-
fected with rAAV-CaMBP4-mCherry (Figure 3C). Thus, BDNF
treatment leads to an increase in inhba expression via an
NMDA-receptor-dependent nuclear calcium signaling pathway.
Given that nuclear calcium regulates CREB/CBP (CREB-
binding protein)-mediated gene expression (Bading, 2013) and
that inhba expression is controlled by CREB (Ardekani et al.,
1998), we investigated a possible involvement of CBP in the
regulation of inhba expression by BDNF. We used rAAV to ex-
press the adenovirus protein E1A, which binds to CBP via itsrs
Figure 3. Inhba—A BDNF-, Nuclear-Calcium-, and CBP-Regulated Neuroprotective Gene
(A) qRT-PCR analysis of inhba expression illustrating the dependence of BDNF-induced expression of inhba on action potentials and NMDA receptor activation.
(B) ELISA analysis of activin A protein expression and secretion using culture media from hippocampal neurons stimulated for the indicated times with BDNF
(100 ng/ml; n = 4).
(C and D) qRT-PCR analysis of inhba expression illustrating the effects of inhibition of nuclear calcium signaling (C), and CBP function (D) on BDNF-induced
expression of inhba. Uninfected hippocampal neurons and neurons infected with the indicated rAAVs were stimulated for 4 hr with 100 ng/ml BDNF in the
presence of TTX (1 mM) or MK-801 (20 mM) where indicated (n = 4).
(E) NMDA-induced cell death in untreated hippocampal neurons and neurons pre-treated for 8 hr with BDNF (100 ng/ml), recombinant activin A (100 ng/ml), or a
combination of both (n = 4).
(F) qRT-PCR analysis of inhba expression in uninfected hippocampal neurons and in hippocampal neurons infected with rAAV-control-RNAi or rAAV-inhba-RNAi
with or without stimulation for 4 hr with BDNF (100 ng/ml).
(G and H) NMDA-induced cell death in uninfected hippocampal neurons and in neurons infected with the indicated rAAVs with or without pre-treatment for 8 hr
with BDNF (100 ng/ml; G) and in uninfected hippocampal neurons pre-treated for 8 hr as indicated with BDNF (100 ng/ml), follistatin (FST) (400 ng/ml), and
SB431542 (SB) (5 mM; H). Cell death was analyzed 18–20 hr following the excitotoxic insult. Statistical analysis for each experiment was determined by ANOVA;
*p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S3. All data are expressed as mean ± SEM.amino-terminal conserved region 1 (CR1) and disrupts CBP
function (Mauceri et al., 2011). Expression of E1A, but not that
of an inactive mutant of E1A (E1ADCR1) that lacks CR1, inhibited
BDNF-induced inhba expression (Figure 3D). These results
reveal a critical role for CBP in BDNF-induced expression of
inhba in hippocampal neurons, indicating that this genomic
event is controlled by the classical nuclear-calcium-regulated
CREB/CBP transcription factor complex.
Inhba/Activin A Mediates BDNF-Induced
Neuroprotection against Excitotoxicity
Next, we investigated whether the protein encoded by the inhba
gene is sufficient to cause neuroprotection. Treatment with re-
combinant activin A indeed rendered hippocampal neurons
more resistant against NMDA-induced excitotoxicity. Applica-
tion of activin A together with BDNF did not further increase neu-Cellroprotection (Figure 3E), indicating that the effects of activin A
and BDNF are not additive but act through a common neuropro-
tective mechanism.
To address whether inhba is required for BDNF-induced neu-
roprotection, we next used genetic and pharmacological tools to
manipulate BDNF-induced inhba/activin A signaling. First, we
used RNAi to block inhba expression in hippocampal neurons.
Cell death experiments revealed that, compared to control neu-
rons infected with an rAAV carrying a non-targeting shRNA
sequence (rAAV-control-RNAi), in hippocampal neurons in-
fected with rAAV-inhba-RNAi, which reduced both basal and
BDNF-induced expression of inhbamRNA (Figure 3F), pre-treat-
ment with BDNF failed to protect against NMDA-induced
excitotoxicity (Figure 3G). To further investigate this with
pharmacological tools, we used follistatin (FST), a high-affinity
activin-A-binding protein, which prevents the formation of theReports 12, 1353–1366, August 25, 2015 ª2015 The Authors 1357
Figure 4. Patch-Clamp Recordings Show a Reduced NMDA-Receptor-Mediated Conductance after BDNF or Activin A Pre-treatment or
inhba Overexpression
(A–H) Patch-clamp recordings in cultured hippocampal neurons. (A) Current response to bath application of NMDA and glycine (both 20 mM, black bar) measured
at the holding potential of 80 mV is shown. Voltage ramps (200 ms; 110 mV to +80 mV; vertical lines) were recorded before NMDA application, at the peak
NMDA response, and after washout. (B) Analysis of current responses to NMDA at the holding potential (Vhold) of 80 mV is shown (*p < 0.05; **p < 0.005;
Student’s t test). (C–H) Graphs show the current-voltage relationships of the net NMDA conductance with statistical comparisons of the slopes estimated from
(legend continued on next page)
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ActR complex (Harrison et al., 2005) and SB431542, an antago-
nist of the ActR IB (ActRIB) (also known as activin-like kinase 4
[ALK4]) that, however, also affects the related ALK5 and ALK7.
Both compounds abolished BDNF-induced protection against
NMDA-induced excitotoxicity (Figure 3H). Thus, the BDNF-
induced increase in inhba expression and ActR receptor activa-
tion are required for BDNF-induced neuroprotection.
BDNF and inhba/Activin A Reduce the NMDA-Receptor-
Mediated Conductance
Because acute (5–15 min) application of BDNF is well known to
increase synaptic transmission and NMDA-receptor-mediated
currents (see Introduction and Figures S2A and S2B), we next
used whole-cell patch-clamp recordings to investigate any last-
ing effects of prolonged BDNF treatment on the NMDA-recep-
tor-mediated conductance. For these experiments, the NMDA
receptor conductance was further isolated by blocking potas-
sium channels with internal cesium and tetraethylammonium
as well as blocking voltage-gated calcium channels with extra-
cellular nifedipine, verapamil, and cadmium. Under these condi-
tions, NMDA induced a small reversible current at 80 mV
(Figure 4A), which was reduced by BDNF pre-treatment for 12–
24 hr (Figure 4B). These results were normalized for membrane
capacitance, which partly corrects for any differences in cell
size, although BDNF treatment per se did not affect membrane
capacitance or resistance measured before NMDA application
(Figure S4A). These effects were not due to any acute effect of
BDNF, which was not present in the perfusate during recordings.
Using voltage ramps (see Supplemental Experimental Proce-
dures for details), we found that the conductance of NMDA re-
ceptors was slightly reduced in cells pre-treated with BDNF for
12–24 hr (Figure 4C). The effects of BDNF were not due to any
differences in the control current-voltage relationships of the
cells measured in basal conditions before NMDA application
(Figure S4B). The reduction in NMDA-receptor-mediated current
at80 mV and slope conductance at positive potentials was not
apparent in cells pre-treated with BDNF for only 2–4 hr (Figures
4B and 4D). The inclusion of 5 mM EGTA in the pipette internal
solution greatly increased the NMDA conductance by reducing
calcium-mediated desensitization and abolished the effect oflinear fits of the curves at positive voltages (*p < 0.05). Cultures were pre-treated
recombinant activin A (100 ng/ml; 5–10 hr) or were infected with rAAVs containin
either GFP and tdimer or Inhba and tdimer. For EGTA experiments, 5 mM EGTA w
cells in each group measured from at least three independent cell preparations.
(I–L) Patch-clamp recordings from CA1 neurons in acute mouse hippocampal s
pocampal slice obtained from an animal stereotactically injected into the hippoc
(scale bar 200 mm). Higher-magnification images (right panels; scale bar 20 mm) f
expressing neuron. (J) Current measured at the holding potential of 80 mV from
300 ms) of NMDA (300 mM) and glycine (100 mM) at the primary apical dendrite 1
NMDA response. (K and L) Analysis of current responses to NMDA at80 mV (*p
of the net NMDA conductance with statistical comparisons of the linear section o
L) of uninfected CA1 neurons from slices obtained from control mice or from infe
slices of mice stereotactically injected into the hippocampus with the appropriate
measured from at least three mice per group. All recordings were performed in t
AMPA receptors (see Supplemental Experimental Procedures and Figure S4 for
(M) Quantitative analysis of infarct volume used to assess ischemic brain damag
with rAAV-inhba-FLAG. Infarct volumes were measured from 20 silver-stained c
determined by ANOVA; ***p < 0.001; NS, not significant; n = 8 animals per cond
All data are expressed as mean ± SEM.
CellBDNF pre-treatment (Figures 4B and 4E). Thus, BDNF pre-treat-
ment reduces the total steady-state NMDA-receptor-mediated
current consistent with a reduced depolarizing force and calcium
influx induced by excitotoxic bath application of NMDA. Taken
together, these data suggest that the observed BDNF-induced
neuroprotection against excitotoxic stimuli might be due to a
decrease in the response of NMDA receptors following BDNF
treatment.
To test the involvementof theActR in theBDNF-induced reduc-
tion in thewhole-cell NMDA receptor conductance,we tested the
ActR antagonist, SB431542, and found that it blocked the effects
of 12–24 hr BDNF treatment (Figures 4B and 4F). In addition, we
tested direct application of recombinant activin A (5–8 hr) and
overexpression of inhba and found that both caused small reduc-
tions in the NMDA response at80mV and thewhole-cell NMDA
receptor conductance (Figures 4B, 4G, and 4H). To determine
whether activin A acts by directly blocking the NMDA receptor,
we tested acute application of recombinant activin A, which did
not affect NMDA responses (Figures S4C–S4E).
To test whether inhba overexpression could also reduce
NMDA-receptor function in neurons in an ex vivo acute slice
preparation, we made whole-cell patch-clamp recording from
CA1 pyramidal neurons. NMDA responses were evoked with
brief pressure applications at the primary apical dendrite (Fig-
ures 4I and 4J) rather than using bath application, which requires
too long to reach amaximal plateau response (Mu¨ller et al., 2006;
data not shown). Again, inhba overexpression using rAAV-hSyn-
inhba-HA/hSyn-tdimer stereotactically delivered to the mouse
hippocampus (see Supplemental Experimental Procedures)
reduced the NMDA response at 80 mV (Figure 4K) and the
whole-cell NMDA receptor conductance (Figure 4L) in compari-
son to expression of a GFP-tdimer control (rAAV-hSyn-eGFP-
HA/hSyn-tdimer) or uninfected neurons from control mice.
Thus, prolonged BDNF treatment reduces NMDA-receptor func-
tion via a process that requires the ActR and is mimicked by
recombinant activin A or overexpression of inhba in culture or
in vivo.
To validate this result in a patho-physiological context, we
examined the effect of inhba/activin A to reduce NMDA-recep-
tor-mediated excitotoxicity in an in vivo model for ischemicas indicated with BDNF (100 ng/ml; 12–24 hr or 2–4 hr), SB431542 (5 mM), or
g expression cassettes with two separate human synapsin promoters driving
as included in the internal solution. Numbers in histograms are the numbers of
lices. (I) Bright-field (upper panels) and tdimer (lower panels) images of a hip-
ampus with an rAAV containing an expression cassette for Inhba and tdimer
rom the same slice show a patch pipette recording from an Inhba- and tdimer-
a CA1 pyramidal neuron showing a response to puff application (black bar;
20 mm from the soma is shown. A voltage ramp is recorded at the peak of the
< 0.05; Student’s t test; K) and graphs showing the current-voltage relationship
f the curves at positive voltages (*p < 0.01; Student’s t test; n.s., not significant;
cted CA1 neurons expressing either GFP and tdimer or Inhba and tdimer from
rAAVs are shown. Numbers in histograms are the number of cells in each group
he presence of blockers of voltage-activated Na+, K+, and Ca2+ channels and
further details).
e after sham surgery or MCAO in mice stereotactically injected into the cortex
oronal brain sections (see also Figure S4) per animal. Statistical analysis was
ition.
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stroke. We found that stereotactic delivery of rAAV-inhba-FLAG
into the cerebral cortex of mice reduced ischemic brain damage
induced by focal middle cerebral artery occlusion (MCAO)
(Figure 4M).
BDNF Reduces the NMDA-Activated Calcium Load
through a Mechanism Requiring Induction of inhba
Transcription
Given that BDNF reduces the NMDA-receptor-mediated con-
ductance, a possible mechanism through which BDNF confers
neuroprotection against NMDA-induced excitotoxicity may
involve reduced NMDA-induced calcium load. Using Fluo-3 cal-
cium imaging, we found no difference in the NMDA-induced cal-
cium response in control and BDNF pre-treated hippocampal
neurons (Figures 5A and 5B). NMDA responses did not exceed
90% of the ionomycin-determined Fmax, showing that the indica-
tor was not saturated. Furthermore, calcium imaging with the
lower-affinity calcium indicators, XRhod-1 and Fluo-5F, pro-
duced similar results to those obtained with Fluo-3 (data not
shown). Because L-type calcium channels contribute signifi-
cantly to the calcium transients evoked by NMDA application,
we repeated the imaging experiments in the presence of the
L-type calcium channel blocker, nifedipine. This revealed a large
reduction in NMDA-induced calcium load in BDNF pre-treated
cells compared to control cells (Figures 5A and 5B), which was
blocked by the TrkB tyrosine kinase inhibitor, K252a, applied
during the period of BDNF treatment (Figures 5C and 5D).
Thus, BDNF treatment and TrkB activation lead to a reduced
NMDA-induced calcium influx in hippocampal neurons.
We next investigated whether inhba is the signaling intermedi-
ate in reducing the NMDA-evoked calcium load after BDNF pre-
treatment. Indeed, we found that both infection of the neurons
with rAAV-inhba-RNAi to knock down inhba expression or treat-
ment with the ActR antagonist, SB431542, abolished the BDNF-
induced reduction in the responsiveness of neurons to bath
application of NMDA (Figures 5E–5H), indicating that inhba pro-
tein expression and the activation of its receptor is necessary for
the BDNF-induced reduction in NMDA-evoked calcium load.
Next, we determined whether activin A is sufficient to reduce
NMDA-induced calcium influx andwhether short-term treatment
of hippocampal neurons with activin A or BDNF would affect
NMDA-induced calcium influx. We found that long-term (over-
night) as well as short-term (4 hr) treatment of neurons with
activin A were both sufficient, whereas only long-term, but not
short-term, treatment of neurons with BDNF was sufficient to
reduce NMDA-induced calcium influx (Figures 5I, 5J, S5A, and
S5B). The lack of effect of a short-term BDNF application is in
line with the involvement of activin A as the functionally relevant
use-dependent effector in this adaptive response whose upre-
gulated expression and secretion in response to BDNF treat-
ment requires longer than 4 hr.
The calcium response of hippocampal neurons to NMDA bath
application was also reduced by overexpression of inhba using
an rAAV or by treatment of uninfected neurons with activin
A-enriched conditioned medium from rAAV-inhba-infected neu-
rons (verified by ELISA analysis; Figures S5C, 5K, and 5L). In
neurons expressing CaMBP4-mCherry to block nuclear calcium
signaling, the NMDA-induced calcium response was no longer1360 Cell Reports 12, 1353–1366, August 25, 2015 ª2015 The Authoreduced by BDNF pre-treatment; however, it was reduced by
the application of activin A (Figures 5M and 5N). Thus,
activin A acts downstream of nuclear calcium signaling to reduce
NMDA-receptor function.
In neurons treated with activin A or neurons infected with rAAV
to express inhba/activin A, we detected a reduced phosphoryla-
tion of the NR2B (GluN2b) subunit of the NMDA receptor at tyro-
sine residue 1472 (Figures 5Q and 5R). This dephosphorylation
event is known to trigger AP-2-mediated endocytosis of NR2B
to reduce the surface expression of NMDA receptors (Nakazawa
et al., 2001; Prybylowski et al., 2005; Roche et al., 2001). These
data suggest that activin A, which is transcriptionally induced
following BDNF treatment via a synaptic NMDA receptor-nuclear
calcium signaling pathway (see Figure 3), acts directly or indi-
rectly to reduce NMDA receptor surface expression, whole-cell
conductance, and toxic calcium influx activated by NMDA appli-
cation via dephosphorylation of NR2B subunit at tyrosine residue
1472. In this scenario, the reduced responses to NMDA after
BDNF pre-treatment would comprise an increased contribution
from NR2A subunit containing NMDA receptors, which have a
smaller steady-state conductance due to calcium-mediated
desensitization (Krupp et al., 1996) and may explain the sensi-
tivity of the BDNF-induced reduction in the NMDA receptor
conductance to intracellular calcium buffers (see Figure 4E).
Given that activin A may act in a paracrine fashion, it is conceiv-
able that, within a neuronal network, neurons that have not
been directly stimulated by BDNF or are unable to activate the
BDNF-nuclear calcium-inhba pathway (for example due to lack
of TrkB or an inability to fire action potentials) still benefit from
the BDNF-stimulated production and secretion of activin A
from surrounding neurons.
BDNF Acting via inhba/Activin A Renders Neurons
Resistant to NMDA-Induced Mitochondrial Dysfunction
One of the earliest events in NMDA-receptor-mediated excito-
toxicity is the overload of mitochondria with calcium ions that
can trigger the collapse of themitochondrial membrane potential
(MMP) and the release of mitochondrial apoptotic proteins into
the cytoplasm (Kroemer et al., 2007). Using rhodamine 123
(Rh123) and TMRE imaging, we found that pre-treatment of
hippocampal neurons with BDNF dramatically reduced the
NMDA-induced loss of MMP (Figures 6A–6H and S6A–S6F).
This BDNF-induced protection against MMP breakdown is
dependent on TrkB activation and neuronal activity because it
failed to build up under conditions where TrkB was inhibited
with K252a or neurons were silenced with TTX during the period
of BDNF treatment (Figures 6A–6G).
The BDNF-induced protection against MMP breakdown
was abolished by infecting the neurons with rAAV-CaMBP4-
mCherry (Figures 6H–6K), which inhibited BDNF/nuclear-
calcium-induced inhba expression (see Figure 3E) and by
antagonizing the action of activin A using the ActR blocker,
SB431542 (Figures 6L–6N). Conversely, infection of neurons
with rAAV-inhba-RNAi to knock down inhba was sufficient to in-
crease the NMDA-induced calcium influx (Figures S7A and S7B)
and rendered mitochondria susceptible to NMDA-induced cyto-
solic calcium overload (Figures S7C–S7E). These results indicate
that the neuroprotective module ‘‘BDNF-nuclear calcium-inhba’’rs
Figure 5. BDNF Acts through Activin A to Reduce NMDA-Evoked Calcium Overload and NR2B Phosphorylation on Tyrosine 1472
(A–P) Fluo-3 imaging of calcium responses induced by NMDA (20 mM) in untreated hippocampal neurons or hippocampal neurons pre-treated with 100 ng/ml for
16 hr (except in I and J) with BDNF or activin A. Traces represent mean values of somatic recordings from at least 120 neurons from n R 3 independent ex-
periments, and histograms show the quantification of the area under the curve (AUC) of the Fluo-3 signals. All calcium imaging was performed in TTX (0.1 mM) and
nifedipine (5 mM) except the indicated experiments in (A) and (B). (A and B) The addition of nifedipine revealed a reduced NMDA-evoked calcium influx after BDNF
pre-treatment. (C–H) The BDNF-induced reduction in calcium responses to NMDAwere blocked by the TrkB blocker K252a (200 nM; C and D), by knockdown of
inhba expression with rAAV-inhba-RNAi (E and F), or by application of the activin-A receptor antagonist, SB431542 (5 mM; G and H). (I and J) Four-hour treatment
with activin A (100 ng/ml), but not with BDNF (100 ng/ml), reduces the NMDA-induced calcium response. (K and L) Infection of hippocampal neurons with rAAV-
inhba-FLAG, but not with the control virus, rAAV-mCherry, reduces the NMDA-induced calcium response. Incubating neurons with media from rAAV-inhba-
FLAG-infected, but not from rAAV-mCherry-infected, cultures was also sufficient to reduce NMDA responses. (M–P) Infection of hippocampal neurons with
rAAV-CaMBP4-mCherry, but not with the control viruses rAAV-mCherry or rAAV-mutCaMBP4-mCherry, blocks the reduction in NMDA-induced calcium
response caused by BDNF (100 ng/ml; 16 hr), but not by activin A (100 ng/ml; 16 hr) pre-treatment. Statistical analysis for each experiment was determined by
ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001.
(Q and R) Immunoblot analysis with antibodies to NR2B and antibodies to the Tyr1472-phosphorylated form of NR2B of lysates from hippocampal neurons
treated for the indicated time with 100 ng/ml activin A (Q; ratio pTyr1472/total NR2B normalized to 0 hr time point. 0 hr: 100%; 2 hr: 73.14% ± 2.82%, ***p < 0.001;
4 hr: 69.63% ± 4.78%, ***p < 0.001; 8 hr: 67.39% ± 6.56%, ***p < 0.001; Student’s t test; n = 10) and of lysates from uninfected hippocampal neurons and from
hippocampal neurons infected with rAAV-inhba-FLAG or rAAV-hrGFP (R; ratio pTyr1472/total NR2B normalized to uninfected control. No virus: 100%; hrGFP:
96.27% ± 9.35%, *p < 0.05; inhba: 62.60% ± 8.70%, *p < 0.05; Student’s t test; n = 5).
See also Figure S5. All data are expressed as mean ± SEM.impinges on mitochondria to shield them from NMDA-induced
dysfunction.
BDNF and inhba/Activin A Reduce Toxic Extrasynaptic
NMDA Receptor Signaling
The activation of extrasynaptic NMDA receptors is known to
trigger MMP breakdown and is attributed with neurotoxic func-Celltion in vitro and in stroke and neurodegenerative disease models
in vivo (Hardingham and Bading, 2010; Parsons and Raymond,
2014). Given the neuroprotective function of the BDNF-nu-
clear-calcium-signaling-inhba pathway and the associated
reduction in NMDA-activated whole-cell conductance, calcium
influx, and MMP breakdown, we reasoned that BDNF and
inhba/activin A trigger a selective reduction in extrasynapticReports 12, 1353–1366, August 25, 2015 ª2015 The Authors 1361
Figure 6. Blockade of Synaptic Activity, Nuclear Calcium Signaling, or Activin A Signaling Abolishes the BDNF-Induced Protection against
Mitochondrial Dysfunction
(A–F ) Rh123 imaging and AUC analysis of NMDA-induced breakdown of the mitochondrial membrane potential in untreated hippocampal neurons and hip-
pocampal neurons treated as indicated with BDNF (100 ng/ml), TTX (1 mM; A–C), and K252a (200 nM; D–F).
(G) TMRE imaging of NMDA-induced breakdown of mitochondrial membrane potential for conditions as shown with Rh123 in (A)–(F). Statistical analysis for each
experiment was determined by ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001.
(H–N) Rh123 imaging and AUC analysis of NMDA-induced breakdown of mitochondrial membrane potential in uninfected hippocampal neurons and in neurons
infected with rAAV-mCherry or rAAV-CaMBP4-mCherry with or without BDNF pre-treatment (H–K) or in untreated hippocampal neurons and in neurons treated
with BDNF or BDNF and SB431542 (5 mM; L–N).
The collapse of mitochondrial membrane potential in (A)–(F) and (H)–(N) was initiated with 20 mMNMDA for 4 min followed by washout of NMDA and treatment at
the indicated time with the mitochondrial uncoupler FCCP (5 mM; arrow) to obtain the maximal Rh123 signals. Traces (A, D, H, I, and L) represent mean values of
Rh123 fluorescence normalized to the peak response to FCCP from at least 120 neurons from nR 3 independent experiments per conditions. Histograms show
the respective AUC analysis of the Rh123 fluorescence traces between the onset of NMDA and FCCP applications.
See also Figures S6 and S7. All data are expressed as mean ± SEM.NMDA-receptor function. To investigate a causal link between
BDNF, activin A, and extrasynaptic NMDA-receptor function,
we used a protocol to isolate extrasynaptic NMDA receptors in
cultured hippocampal neurons by blocking synaptic NMDA re-
ceptors selectively with the use-dependent blocker, MK-801,
applied in the presence of an activator of bursts of synaptic ac-
tivity. Following washout of MK-801, extrasynaptic NMDA re-
ceptors were quantified with Fluo-3 calcium imaging in the
presence of blockers of voltage-operated calcium channels
and action potentials (Figure 7A). We found that overnight pre-
treatment with BDNF prior to the imaging experiment caused a1362 Cell Reports 12, 1353–1366, August 25, 2015 ª2015 The Authodramatic reduction in the amplitude of extrasynaptic NMDA
receptor-evoked calcium signals evoked by NMDA at the
same duration and concentration as that used to induce neuro-
toxicity (i.e., 10 min; 20 mM; Figure 7B). This BDNF-induced
reduction in extrasynaptic NMDA-receptor function was sensi-
tive to SB431542, indicating the involvement of ActR (Figure 7C).
In line with this, overexpression of inhba following infection of
hippocampal neurons with rAAV-inhba-FLAG (alongside rAAV-
mCherry to identify infected neurons) mimicked the effects
of BDNF in reducing extrasynaptic NMDA-receptor function
(Figure 7D).rs
Figure 7. BDNF Pre-treatment Reduces
Extrasynaptic NMDA-Receptor-Mediated
Calcium Influx
(A) Extrasynaptic NMDA-receptor-mediated cal-
cium responses in cultured hippocampal neurons.
Representative recording from one coverslip
showing 112 traces from individual neurons in gray
and their average in black is shown. NMDA (20 mM)
and glycine (100 mM) were applied (black bar) after
blockade of synaptic NMDA receptors and sub-
sequent blockade of voltage-gated sodium and
calcium channels and AMPA receptors (see the
Supplemental Experimental Procedures).
(B–D) Quantification of calcium levels before
(baseline) and after 5 and 10 min of NMDA +
glycine application, expressed as the peak
response amplitude (peak  baseline) or AUC
(integral above baseline). (B) A 12–24 hr pre-
treatment with BDNF (100 ng/ml) reduces NMDA +
glycine responses. (C) The BDNF-induced reduc-
tion in extrasynaptic NMDA receptor responses is
blocked by SB431542 (5 mM) in parallel experi-
ments. (D) Viral-vector-mediated expression of
Inhba and mCherry, which identifies infected hip-
pocampal neurons, mimics the BDNF-induced
reduction in extrasynaptic NMDA receptor re-
sponses in comparison to mCherry expression
alone. Note that BDNF was not present during any
recordings. Data for each panel were obtained in
parallel from 200–230 cells from 9–10 coverslips
(B) or 500–670 cells from 4–7 coverslips (C and D)
for each condition. Fewer cells per coverslip were
recorded in the experiments in (B) due to a smaller
field of view. *p < 0.01; **p < 0.0001.
(E) Schematic model illustrating the link between
BDNF, nuclear calcium signaling, activin A,
synaptic versus extrasynaptic NMDA receptor
signaling, and neuronal health.
All data are expressed as mean ± SEM.Taken together, our results show that BDNF acts through
a transcription loop that stimulates the expression of inhba;
the increased production and secretion of activin A and subse-
quent activation of its cognate receptor leads to a reduction of
calcium influx mediated by neurotoxic extrasynaptic NMDA
receptors.
DISCUSSION
In this study, we show that the function of BDNF as an activator
of synaptic activity underlies its ability to promote survival of hip-
pocampal neurons against oxidative stress and excitotoxicity.
The neuroprotective mechanism triggered by BDNF treatment
ismediated by synaptic NMDA receptor activation, causing a nu-
clear-calcium-regulated genomic response, which via increased
inhba expression, secretion into the extracellular space, and
activation of ActR leads to a reduction in neurotoxic extrasynap-
tic NMDA-receptor-mediated calcium influx, which shields mito-
chondria from excitotoxicity-associated dysfunction (Figure 7E).
These findings challenge the prevalent view that BDNF-evokedCellPI3K/Akt and ERK1/2 signaling and the activation of down-
stream effector molecules, such as Bad (Datta et al., 1997), are
primarily responsible for the neuroprotective functions of BDNF
(Almeida et al., 2005; Atwal et al., 2000; Han and Holtzman,
2000; Hetman et al., 1999). Indeed, a lack of contribution of either
ERK1/2 or PI3K or both to BDNF-induced neuroprotection has
been suggested previously (Han and Holtzman, 2000; Hetman
et al., 1999; Klo¨cker et al., 2000). Such discrepancies may be
due to differences in the toxic stimulus, the developmental state
of the tissue, and possibly also non-selective pharmacological
actions of the ERK1/2 and PI3K inhibitors used (Gharbi et al.,
2007; Wauson et al., 2013). For example, synaptic connectivity,
which is present in our culture networks at days in vitro (DIV)
10–12 (Arnold et al., 2005; Hardingham et al., 2001) but absent
in 6- to 7-day-old cultures (data not shown), is necessary for
the nuclear calcium signaling and transcriptional responses
to BDNF.
Our results revealed that BDNF is not only a component of ac-
tivity-dependent neuroprotection (Ghosh et al., 1994) but that it
exerts its neuroprotective function in hippocampal neuronsReports 12, 1353–1366, August 25, 2015 ª2015 The Authors 1363
principally through stimulating synaptic activity, the generation
of nuclear calcium signals, and the induction of genomic re-
sponses. One important implication of these findings is that other
biological effects of BDNF, for instance during development or in
diseases, may have to be viewed in light of the ability of BDNF to
promote synaptic activity. BDNF-induced long-term survival
may not primarily result from its neurotrophic actions as previ-
ously thought but could rather reflect the consequence of activ-
ity-dependent neuroprotection, which together with the effect of
BDNF to promote neuronal differentiation and synaptogenesis
(Park and Poo, 2013) and area-specific dendritic growth (Raus-
kolb et al., 2010) may support the integration of isolated
and initially possibly vulnerable neurons into functionally stable
neuronal networks.
In light of the observed links between BDNF, neuronal activity,
and synaptic NMDA receptors, it may be necessary to reassess
the process through which BDNF or the lack of it contributes to
neuropathology. Previous studies argue that neuronal cell death
in Alzheimer’s disease (AD), Huntington’s disease (HD), or
Parkinson’s disease (PD) occur as a consequence of disease-
specific factors, which lead to a deficiency in neurotrophic
support by BDNF (Zuccato and Cattaneo, 2009). Our findings
suggest that reduced levels of BDNF could, in addition to
decreasing trophic support, compromise neuronal activity, the
balance between synaptic versus extrasynaptic NMDA receptor
signaling, and the ability to generate nuclear calcium signals,
which are essential for the activation of neuroprotective genes.
Consequently, neurons deprived of BDNF and BDNF-evoked
activity may be more vulnerable to cellular stresses due
to engagement of neurotoxic extrasynaptic NMDA receptor
signaling and reduced expression of activity- and calcium-
signal-regulated genes critical, for example, for the stabilization
and strengthening of mitochondrial functions (Lau and Bading,
2009; Zhang et al., 2009) and/or for the initiation and mainte-
nance of antioxidant defenses (Papadia et al., 2008). Because
BDNF can enhance the efficacy of synaptic transmission (Poo,
2001) but itself is also subject to regulation by neuronal activity
(Ghosh et al., 1994; Hardingham et al., 2002), an initial decrease
in BDNF levels caused by disease-specific factors (Zuccato and
Cattaneo, 2009) may trigger a self-reinforcing gradual decline of
synaptic activity and network function, leading to a pathological
state of compromised cell health. Therapeutic intervention
aimed at enhancing BDNF signaling may break this vicious cir-
cle. However, local administration of BDNF in clinical settings
has proven only moderately successful for several reasons
including the short half-life of BDNF, its poor blood-brain barrier
penetration, and the unwanted side effects such as severe
cognitive impairment or even epileptic seizures (Thoenen and
Sendtner, 2002). The implication of the concept of ‘‘BDNF as
an enhancer of synaptic activity- and calcium-regulated pro-
cesses’’ is that possible treatments of neurodegenerative dis-
eases would not necessarily need to include the application of
BDNF. Therapeutic strategies that support and enhance synap-
tic activity by using either pharmacological means or even
mental exercises and living an active lifestyle may prove useful.
In line with this, optogenetic stimulation has recently been shown
to aid recovery after stroke (Cheng et al., 2014) and the benefits
of physical exercise on cognition are mediated by BDNF1364 Cell Reports 12, 1353–1366, August 25, 2015 ª2015 The Autho(Gomez-Pinilla et al., 2008). Indeed, activity-induced transcrip-
tion of bdnf may create the positive feedback loop required for
sustained neuroprotection and survival, circumventing the diffi-
culties and side effects associated with BDNF administration.
In addition, the delivery of downstream targets of BDNF and
synaptic activity, in particular inhba/activin A, as well as the
development of agonists of ActR signaling may prove an effec-
tive strategy to boost neuroprotection and combat neuron loss
in neurodegenerative diseases including AD, HD, and PD, in
which impaired synaptic activity, imbalanced synaptic versus
extrasynaptic NMDA receptor activation, and dysfunctional
BDNF signaling are early hallmarks (Hardingham and Bading,
2010; Parsons and Raymond, 2014; Zuccato and Cattaneo,
2009). Encouraging results have already been obtained using ac-
tivin A as a neuroprotective agent in a rat lesion model of HD
(Hughes et al., 1999). Recent work demonstrated that overex-
pression of mutant huntingtin induces phosphorylation of the
NR2B subunit at tyrosine residue 1472 in vitro (Song et al.,
2003), sensitizes NMDA receptors, and induces excitotoxicity
in vivo (Zeron et al., 2002), indicating that cell loss in HD (and
perhaps also in other neurodegenerative diseases; Li et al.,
2011) may result from a shift in the balance of NMDA receptor
signaling from the survival-promoting synaptic NMDA receptor
toward extrasynaptic NMDA receptors that initiate cell death
pathways (Hardingham et al., 2002; Hardingham and Bading,
2010; Parsons and Raymond, 2014). By showing that BDNF/
inhba signaling regulates and restores the balance in NMDA
receptor signaling by affecting phosphorylation of the NR2B
subunit at tyrosine residue 1472 and reducing the toxic, extrasy-
naptic NMDA-receptor-induced calcium influx, our data causally
link these findings by delivering an explanation as to how activin
A may rescue BDNF-deficient neurons from neuronal dysfunc-
tion and cell death associated with, or caused by, an imbalance
in extrasynaptic versus synaptic NMDA receptor signaling. It
describes an alternative BDNF-dependent neuroprotective
pathway involving the activation of synaptic NMDA receptors,
nuclear calcium signaling, and the induction and expression of
activin A to regulate the balance between extrasynaptic versus
synaptic NMDA receptor signaling and thus provide a mecha-
nism that may help to understand pathological processes under-
lying HD and other neurodegenerative diseases.EXPERIMENTAL PROCEDURES
Cell Culture and Cell Death Assays
Hippocampal neurons from newborn C57Bl6N mice were prepared and
maintained as described previously (Zhang et al., 2007). Experiments were
performed after a culturing period of 10–13 DIV, during which hippocampal
neurons express functional glutamate receptors (NMDA/AMPA/kainate) and
develop an extensive network of synaptic contacts. Excitotoxicity in hippo-
campal neurons was triggered by a 10 min exposure of neurons to 20 mM
NMDA. After several washes with medium, neurons were left for an additional
18–20 hr before analysis. One hour before the termination of the experiment,
1 mM calcein (Molecular Probes), a cell-permeable esterase-activated fluoro-
phore, was added to the culture medium. Cell were fixed with 4% parafor-
maldehyde for 15 min, washed with PBS, and counterstained with Hoechst
33258 (2 mg/ml) for 10 min. Coverslips were mounted in Mowiol and
examined by fluorescence microscopy, whereby dead neurons were scored
as calcein negative with amorphous or shrunken nuclei visualized with
Hoechst.rs
rAAVs
Viral particles were produced and purified as described previously (Zhang
et al., 2007). Cultured neurons were infected with 2–5 3 109 particles/ml on
DIV 4–6 and harvested or analyzed on DIV 10–13.
Animals and Stereotactic Injection
All in vivo experiments were done using young adult C57/Bl6N mice. rAAVs
were delivered by stereotactic injections. To target the dorsal hippocampus
for acute slice preparation and electrophysiological experiments, a total vol-
ume not exceeding 3 ml containing a 3:1 mixture of 33 108 genomic virus par-
ticles and 20% Mannitol (Fresenius) were injected bilaterally at the following
coordinates relative to Bregma: anteroposterior (AP) 2.1 mm; mediolateral
(ML) ±1.6 mm; dorsoventral (DV) 1.3/1.4/1.5 mm using a stereotactic frame
(Kopf Instruments). For MCAO experiments, 2.0 ml of either PBS or rAAV-
inhba-FLAG (1 to 2 3 109 genomic virus particles) was injected unilaterally
into the cerebral cortex at the following coordinates: first site: AP 0.2 mm;
ML 2.0; DV 2.0; second site: AP 0.2; ML 2.0; DV 1.8; third site: AP 0.2;
ML 3.0; DV 4.0; and fourth site: AP 0.2; ML 3.0; DV 3.5 from Bregma.
Mixture of virus particles with or without Mannitol was infused at a rate of
200 nl/min using a microprocessor-controlled mini-pump (World Precision
Instruments). All animal experiments were approved by the local animal
welfare committee (Regierungspra¨sidium Karlsruhe, Germany).
For additional details on methods used in this study, see the Supplemental
Experimental Procedures.
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